PharmaMar (MSE:PHM) is taking part in the 10th China Healthcare Investment Conference (CHIC) in Shanghai, China, from 26th to 28th March.
Madrid, 26th of March, 2019.- PharmaMar (MSE:PHM) is taking part in the 10th China Healthcare Investment Conference (CHIC) in Shanghai, China, from 26th to 28th March. The Spanish biopharmaceutical company will meet with investment funds in order to tackle business development and publicize the latest advances in its clinical developments.
On Thursday 28th March at 10:25 (GMT +8), José María Fernández Sousa-Faro, Chairman of PharmaMar, will present the Company and the latest developments in lurbinectedin in microcytic lung cancer during the session entitled “Pharmaceuticals & Biotech II: Global Biotech Presentations” to an audience of approximately 2,000 investors.
According to data from the World Health Organization (WHO), China has the highest number of cancer cases in the world, due to population ageing, tobacco or pollution, and China is the country with the highest mortality rate in Asia for lung cancer. This type of tumor affects a larger number of people than in the U.S., Europe and Japan combined. The WHO estimates that by 2020 800,000 new cases of lung cancer will be diagnosed and will cause nearly 700,000 deaths.
Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About PharmaMar
Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.
PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at www.pharmamar.com.
About lurbinectedin
Lurbinectedin (PM1183) is a compound under clinical investigation. It is an inhibitor of RNA polymerase II. This enzyme is essential for the transcription process that is over-activated in tumors with transcription addiction.
Media Contact:
Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000
Investor Relations:
Phone: +34 914444500
Or please visit our website at www.pharmamar.com
